These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors. Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T. Digestion; 2013; 87(1):47-52. PubMed ID: 23343969 [Abstract] [Full Text] [Related]
4. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. Zhu J, Yang Y, Zhou L, Jiang M, Hou M. BMC Cancer; 2010 May 13; 10():199. PubMed ID: 20465813 [Abstract] [Full Text] [Related]
5. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study. Qi J, Liu HL, Ren F, Liu S, Shi W, Liu WH, Cai GQ, Liao GQ. World J Surg Oncol; 2020 Apr 07; 18(1):70. PubMed ID: 32264886 [Abstract] [Full Text] [Related]
6. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Ann Surg Oncol; 2007 Jan 07; 14(1):14-24. PubMed ID: 17072676 [Abstract] [Full Text] [Related]
10. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Eur J Surg Oncol; 2014 Apr 07; 40(4):420-8. PubMed ID: 24238762 [Abstract] [Full Text] [Related]
11. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. J Gastrointest Cancer; 2014 Dec 07; 45(4):431-40. PubMed ID: 24847952 [Abstract] [Full Text] [Related]
12. Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure. Yang W, Yu J, Gao Y, Shen Q, Zhang Q, Liu X, Zhao Z, Shi X, Zhu K, Ma Y. Med Oncol; 2014 Sep 07; 31(9):133. PubMed ID: 25056206 [Abstract] [Full Text] [Related]
14. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors. Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H. J Surg Oncol; 2014 Dec 07; 110(8):942-6. PubMed ID: 25164620 [Abstract] [Full Text] [Related]
16. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report. Kimura T, Togawa T, Onishi K, Iida A, Sato Y, Goi T. J Investig Med High Impact Case Rep; 2020 Dec 07; 8():2324709620970736. PubMed ID: 33228387 [Abstract] [Full Text] [Related]
18. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Eur J Surg Oncol; 2014 Apr 07; 40(4):412-9. PubMed ID: 24491288 [Abstract] [Full Text] [Related]